In a move to bolster its immuno-oncology portfolio, Takeda Pharmaceutical has exercised its option to acquire Adaptate Biotherapeutics for an undisclosed amount.With the deal, Takeda will gain rights to Adaptate’s antibody-based gamma delta T cells engager platform, including preclinical candidates and discovery pipeline programmes. The deal comes three months after Takeda exercised its option to acquire GammaDelta for its allogeneic variable delta 1 gamma delta T cell therapy platforms, which includes both blood-derived and tissue-derived platforms. Takeda aims to enhance its oncology portfolio by leveraging the use of gamma deltaT cells.